Abstract:Precise combination therapy, involving multiple chemotherapeutics with pharmacologically synergistic antitumor effects, is a promising approach to address the challenge of monotherapy with insufficient activity towards their targets of interest. We employed PtFpyridine coordination-driven assembly to construct a stoichiometric coordination complex of camptothecin and organoplatinum (II) (Pt-CPT). The Pt-CPT complex exhibited a remarkable synergistic effect toward several tumor cell lines, which is equal to the optimal synergistic effect of (PEt3)2Pt(OTf)2 (Pt) and CPT mixture at various ratios. An amphiphilic polymer with H2O2-responsiveness and glutathione (GSH)-depleting ability ( PO ) was used to encapsulate Pt-CPT complex to enable the nanomedicine (Pt-CPT@PO) with prolonged blood cir-culation and elevated tumor accumulation. The Pt-CPT@PO nanomedicine exhibited remarkable syn-ergistic antitumor efficacy and antimetastatic effect on a mice orthotopic breast tumor model. This work demonstrated the potential of stoichiometric coordination-driven assembly of organic therapeu-tics with metal-based drugs in developing advanced nanomedicine with optimal synergistic antitumor activity.Statement of significanceIn this study, for the first time, we employed PtFpyridine coordination-driven assembly to construct a stoichiometric coordination complex of camptothecin and organoplatinum (II) (Pt-CPT), with an optimal synergistic effect at various ratios. Then it was encapsulated into an amphiphilic polymer with H2O2-responsiveness and glutathione (GSH)-depleting ability ( PO ) to enable the nanomedicine (Pt-CPT@PO) with prolonged blood circulation and elevated tumor accumulation. The Pt-CPT@PO nanomedicine ex-hibited remarkable synergistic antitumor efficacy and antimetastatic effect on a mice orthotopic breast tumor model.(c) 2023 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.

Dual-targeting antitumor hybrids derived from Pt(IV) species and millepachine analogues.

Nanoparticle Delivery of a Triple-Action Pt(iv) Prodrug to Overcome Cisplatin Resistance Via Synergistic Effect

Delivery of Platinum (II) Drugs with Bulky Ligands in Trans-Geometry for Overcoming Cisplatin Drug Resistance.

Pt(IV) Prodrugs Containing Microtubule Inhibitors Displayed Potent Antitumor Activity and Ability to Overcome Cisplatin Resistance.

Dual Mitochondria- and DNA-Targeting Coumarin-Pt(IV) Prodrug for the Enhancement of Anticancer Performance

Platinum(IV) Complexes Conjugated with Phenstatin Analogue As Inhibitors of Microtubule Polymerization and Reverser of Multidrug Resistance.

Hybrid of DNA-targeting Chlorambucil with Pt(IV) Species to Reverse Drug Resistance

A Nanomedicine Based on Stoichiometric Coordination of Camptothecin and Organoplatinum (II) for Synergistic Antitumor Therapy.

Multiaction Pt(IV) Prodrugs Releasing Cisplatin and Dasatinib Are Potent Anticancer and Anti-Invasive Agents Displaying Synergism between the Two Drugs

Synthesis and Evaluation of Novel Podophyllotoxin Derivatives As Potential Antitumor Agents.

Design, Synthesis, and Structure–activity Relationship Studies of Novel Millepachine Derivatives As Potent Antiproliferative Agents

Ptxplatin: An multifunctional Pt(IV) antitumor prodrug

Dual-targeting tumor cells hybrids derived from Pt(IV) species and NF-κB inhibitors enables cancer therapy through mitochondrial dysfunction and ER stress and overcomes cisplatin resistance

Synthesis and biological evaluation of novel millepachine derivatives as a new class of tubulin polymerization inhibitors.

Combretastatin A-4 Analogue: A Dual-Targeting and Tubulin Inhibitor Containing Antitumor Pt(IV) Moiety with a Unique Mode of Action.

A Dual Stimuli‐responsive Nanoplatform Loaded PtIV‐triptolide Prodrug for Achieving Synergistic Therapy Toward Breast Cancer

Dual-targeting Antitumor Conjugates Derived from Platinum(iv) Prodrugs and Microtubule Inhibitor CA-4 Significantly Exhibited Potent Ability to Overcome Cisplatin Resistance.

Synthesis and biological evaluation of novel millepachine derivative containing aminophosphonate ester species as novel anti-tubulin agents

Design and biological evaluation of dual tubulin/HDAC inhibitors based on millepachine for treatment of prostate cancer

Multitargeted Platinum(IV) Anticancer Complexes Bearing Pyridinyl Ligands as Axial Leaving Groups.

Synthesis, in Vitro and in Vivo Evaluation of New Hybrids of Millepachine and Phenstatin As Potent Tubulin Polymerization Inhibitors